Bolt Biotherapeutics

Bolt Biotherapeutics develops the Boltbody platform, creating Immune-Stimulating Antibody Conjugates (ISACs) as a novel cancer immunotherapy.
Domain
Healthcare
Status
IPO’d/​Acquired
IPO Date
2021
Stage of Initial Investment
Series C
Initial Investment Year
2020